GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camp4 Therapeutics Corp (NAS:CAMP) » Definitions » Total Tax Payable

CAMP (Camp4 Therapeutics) Total Tax Payable : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Camp4 Therapeutics Total Tax Payable?

Camp4 Therapeutics's Total Tax Payable for the quarter that ended in Sep. 2024 was $0.00 Mil.


Camp4 Therapeutics Total Tax Payable Historical Data

The historical data trend for Camp4 Therapeutics's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camp4 Therapeutics Total Tax Payable Chart

Camp4 Therapeutics Annual Data
Trend Dec22 Dec23
Total Tax Payable
- -

Camp4 Therapeutics Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
Total Tax Payable Get a 7-Day Free Trial - - - - -

Camp4 Therapeutics Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.


Camp4 Therapeutics Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Camp4 Therapeutics's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Camp4 Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.